The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
Open accessAbstract
BACKGROUND: Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited. METHODS: We performed a multicenter, randomized, double-blind, adaptive, phase 2-3 trial assessing the efficacy and safety of a pediatric-specific oral propranolol solution in infants 1 to 5 months of age with proliferating infantile hemangioma requiring systemic therapy. Infants were randomly assigned to receive placebo or one of four propranolol regimens (1 or 3 mg of propranolol base per kilogram of body weight per day for 3 or 6 months). A preplanned interim analysis was conducted to identify the regimen to study for the final efficacy analysis. The primary end point was success (complete or nearly complete resolution of the target hemangioma) or failure of trial treatment at week 24, as assessed by independent, centralized, blinded evaluations of standardized photographs. RESULTS: Of 460 infants who underwent randomization, 456 received treatment. On the basis of an interim analysis of the first 188 patients who completed 24 weeks of trial treatment, the regimen of 3 mg of propranolol per kilogram per day for 6 months was selected for the final efficacy analysis. The frequency of successful treatment was higher with this regimen than with placebo (60% vs. 4%, P<0.001). A total of 88% of patients who received the selected propranolol regimen showed improvement by week 5, versus 5% of patients who received placebo. A total of 10% of patients in whom treatment with propranolol was successful required systemic retreatment during follow-up. Known adverse events associated with propranolol (hypoglycemia, hypotension, bradycardia, and bronchospasm) occurred infrequently, with no significant difference in frequency between the placebo group and the groups receiving propranolol. CONCLUSIONS: This trial showed that propranolol was effective at a dose of 3 mg per kilogram per day for 6 months in the treatment of infantile hemangioma. (Funded by Pierre Fabre Dermatologie; ClinicalTrials.gov number, NCT01056341.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An improved Bonferroni procedure for multiple tests of significance
SIMES, R. J. (1986) · Biometrika · doi:10.1093/biomet/73.3.751 · Cited by 2,396
Propranolol for Severe Hemangiomas of Infancy
Léauté-Labrèze, C., de la Roque, E. D., Hubiche, T., Boralevi, F., Thambo, J.-B., & Taïeb, A. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0708819 · Cited by 2,374
Self-citationInterferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Growth Characteristics of Infantile Hemangiomas: Implications for Management
Chang, L. C., Haggstrom, A. N., Drolet, B. A., Baselga, E., Chamlin, S. L., Garzon, M. C., Horii, K. A., Lucky, A. W., Mancini, A. J., Metry, D. W., et al. (2008) · Pediatrics · doi:10.1542/peds.2007-2767 · Cited by 694
Self-citationInitiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference
Drolet, B. A., Frommelt, P. C., Chamlin, S. L., Haggstrom, A., Bauman, N. M., Chiu, Y. E., Chun, R. H., Garzon, M. C., Holland, K. E., Liberman, L., et al. (2013) · Pediatrics · doi:10.1542/peds.2012-1691 · Cited by 591
Self-citationPropranolol for Severe Infantile Hemangiomas: Follow-Up Report
Sans, V., de la Roque, E. D., Berge, J., Grenier, N., Boralevi, F., Mazereeuw-Hautier, J., Lipsker, D., Dupuis, E., Ezzedine, K., Vergnes, P., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-3458 · Cited by 568
Self-citationInfantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature
Kilcline, C., & Frieden, I. J. (2008) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2008.00626.x · Cited by 534
Self-citationProspective Study of Infantile Hemangiomas: Demographic, Prenatal, and Perinatal Characteristics
Haggstrom, A. N., Drolet, B. A., Baselga, E., Chamlin, S. L., Garzon, M. C., Horii, K. A., Lucky, A. W., Mancini, A. J., Metry, D. W., Newell, B., et al. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.12.003 · Cited by 484
Self-citationFrieden, I. J., Haggstrom, A. N., Drolet, B. A., Mancini, A. J., Friedlander, S. F., Boon, L., Chamlin, S. L., Baselga, E., Garzon, M. C., Nopper, A. J., et al. (2005) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2005.00102.x · Cited by 385
Self-citationThe Natural History of the Strawberry Nevus
BOWERS, R. E. (1960) · Archives of Dermatology · doi:10.1001/archderm.1960.01580050009002 · Cited by 356
Research works printed but not linked: 18
- 10.1016/S0190-9622(97)70183-X · doi:10.1016/s0190-9622(97)70183-x
- Hoornweg MJ, 2005, Ned Tijdschr Geneeskd, 149, 2455
- 10.1097/00006534-196701000-00010 · doi:10.1097/00006534-196701000-00010
- Enjolras O, 1990, Pediatrics, 85, 491, 10.1542/peds.85.4.491 · doi:10.1542/peds.85.4.491
- 10.1111/j.1529-8019.2005.05018.x · doi:10.1111/j.1529-8019.2005.05018.x
- 10.1016/j.arcped.2003.10.014 · doi:10.1016/j.arcped.2003.10.014
- 10.1097/PRS.0b013e31827c6fab · doi:10.1097/prs.0b013e31827c6fab
- 10.1001/archdermatol.2011.203 · doi:10.1001/archdermatol.2011.203
- 10.1111/j.1525-1470.2011.01551.x · doi:10.1111/j.1525-1470.2011.01551.x
- 10.1387/ijdb.103221pm · doi:10.1387/ijdb.103221pm
- 10.1016/S0140-6736(00)70042-0 · doi:10.1016/s0140-6736(00)70042-0
- 10.1111/bjd.12432 · doi:10.1111/bjd.12432
- 10.1016/j.jaad.2011.01.025 · doi:10.1016/j.jaad.2011.01.025
- 10.1016/j.jaad.2010.12.040 · doi:10.1016/j.jaad.2010.12.040
- 10.1016/j.jaapos.2010.05.002 · doi:10.1016/j.jaapos.2010.05.002
- 10.1038/eye.2011.233 · doi:10.1038/eye.2011.233
- 10.1001/archoto.2011.55 · doi:10.1001/archoto.2011.55
- 10.1111/j.1440-1754.2012.02521.x · doi:10.1111/j.1440-1754.2012.02521.x
Cited by
Northup, P. G., Garcia‐Pagan, J. C., Garcia‐Tsao, G., Intagliata, N. M., Superina, R. A., Roberts, L. N., Lisman, T., & Valla, D. C. (2021) · Hepatology · doi:10.1002/hep.31646 · Cited by 667
Perioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
Léauté-Labrèze, C., Harper, J. I., & Hoeger, P. H. (2017) · The Lancet · doi:10.1016/s0140-6736(16)00645-0 · Cited by 508
Self-citationClinical Practice Guideline for the Management of Infantile Hemangiomas
Krowchuk, D. P., Frieden, I. J., Mancini, A. J., Darrow, D. H., Blei, F., Greene, A. K., Annam, A., Baker, C. N., Frommelt, P. C., Hodak, A., et al. (2019) · Pediatrics · doi:10.1542/peds.2018-3475 · Cited by 503
Self-citationDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Metadata
- Authors
- Léauté-Labrèze, C., Hoeger, P., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., Phillips, R. J., Caceres, H., Lopez Gutierrez, J. C., Ballona, R., Friedlander, S. F., Powell, J., Perek, D., Metz, B., Barbarot, S., Maruani, A., Szalai, Z. Z., Krol, A., Boccara, O., Foelster-Holst, R., Bosch, M. I., Su, J., Buckova, H., Torrelo, A., Cambazard, F., Grantzow, R., Wargon, O., Wyrzykowski, D., Roessler, J., Bernabeu-Wittel, J., Valencia, A. M., Przewratil, P., Glick, S., Pope, E., Birchall, N., Benjamin, L., Mancini, A. J., Vabres, P., Souteyrand, P., Frieden, I. J., Berul, C. I., Mehta, C. R., Prey, S., Boralevi, F., Morgan, C. C., Heritier, S., Delarue, A., & Voisard, J.-J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 735-746
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2100584705
- Cited by
- 801
- References
- 19
- FWCI
- 77.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. https://app.cochat.ai/papers/10.1056/nejmoa1404710
- The paper
- Léauté-Labrèze, C., Hoeger, P., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., Phillips, R. J., Caceres, H., Lopez Gutierrez, J. C., Ballona, R., Friedlander, S. F., Powell, J., Perek, D., Metz, B., Barbarot, S., Maruani, A., Szalai, Z. Z., Krol, A., Boccara, O., . . . Voisard, J.-J. (2015). A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1404710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
